Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment, and you are unlikely to be protected if something goes wrong.
Tony joined Ablynx as Chief Scientific Officer in October 2013. In this role, he leads the company’s discovery, pharmacology, and CMC organisation. Tony has more than 15 years of biotech R&D experience and expertise in building out pipelines and expanding platform technologies. Prior to joining Ablynx, Tony was CSO at Moderna Therapeutics where he led the science, helping to grow the company from a start-up to an established biotech. Previously, Tony was CSO at Tolerx Inc and prior to that he served on the management team of Alnylam Pharmaceuticals as Vice President, Research, Immunology, Metabolic, and Viral Disease from 2003-2010. He also served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.) from 1998-2003 where he worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics.